JP2025509272A5 - - Google Patents
Info
- Publication number
- JP2025509272A5 JP2025509272A5 JP2024553337A JP2024553337A JP2025509272A5 JP 2025509272 A5 JP2025509272 A5 JP 2025509272A5 JP 2024553337 A JP2024553337 A JP 2024553337A JP 2024553337 A JP2024553337 A JP 2024553337A JP 2025509272 A5 JP2025509272 A5 JP 2025509272A5
- Authority
- JP
- Japan
- Prior art keywords
- caspase
- seq
- antibody
- region
- masked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2022/079475 | 2022-03-07 | ||
| PCT/CN2022/079475 WO2023168547A1 (en) | 2022-03-07 | 2022-03-07 | Anti-cd137 antibodies and methods of making and using the same |
| PCT/CN2023/079843 WO2023169360A1 (en) | 2022-03-07 | 2023-03-06 | Anti-cd137 antibodies and methods of making and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509272A JP2025509272A (ja) | 2025-04-11 |
| JP2025509272A5 true JP2025509272A5 (enExample) | 2026-03-12 |
Family
ID=87936825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553337A Pending JP2025509272A (ja) | 2022-03-07 | 2023-03-06 | 抗ｃｄ１３７抗体ならびにその作製及び使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250188179A1 (enExample) |
| EP (1) | EP4490204A1 (enExample) |
| JP (1) | JP2025509272A (enExample) |
| KR (1) | KR20240170602A (enExample) |
| CN (1) | CN119137159A (enExample) |
| AU (1) | AU2023229660A1 (enExample) |
| CA (1) | CA3244912A1 (enExample) |
| MX (1) | MX2024010847A (enExample) |
| TW (1) | TW202346352A (enExample) |
| WO (2) | WO2023168547A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| WO2019148445A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109651507B (zh) * | 2017-10-12 | 2021-11-26 | 瑞阳(苏州)生物科技有限公司 | 一种激动型4-1bb单克隆抗体 |
| WO2019148445A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| JP7634001B2 (ja) * | 2019-10-11 | 2025-02-20 | ナンチン リーズ バイオラブス カンパニー，リミティド | ４－１ｂｂに結合する抗体およびその用途 |
| CN112794905B (zh) * | 2019-11-13 | 2022-10-04 | 合肥瀚科迈博生物技术有限公司 | 一种能够与人4-1bb结合的分子 |
| CN112898426A (zh) * | 2019-11-19 | 2021-06-04 | 非同（成都）生物科技有限公司 | 人源化4-1bb单克隆抗体及其药物组合物 |
-
2022
- 2022-03-07 WO PCT/CN2022/079475 patent/WO2023168547A1/en not_active Ceased
-
2023
- 2023-03-06 KR KR1020247033366A patent/KR20240170602A/ko active Pending
- 2023-03-06 TW TW112108072A patent/TW202346352A/zh unknown
- 2023-03-06 JP JP2024553337A patent/JP2025509272A/ja active Pending
- 2023-03-06 EP EP23765938.8A patent/EP4490204A1/en active Pending
- 2023-03-06 WO PCT/CN2023/079843 patent/WO2023169360A1/en not_active Ceased
- 2023-03-06 CA CA3244912A patent/CA3244912A1/en active Pending
- 2023-03-06 US US18/842,313 patent/US20250188179A1/en active Pending
- 2023-03-06 AU AU2023229660A patent/AU2023229660A1/en active Pending
- 2023-03-06 CN CN202380037528.3A patent/CN119137159A/zh active Pending
-
2024
- 2024-09-05 MX MX2024010847A patent/MX2024010847A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220017640A1 (en) | Activatable bispecific antibodies | |
| KR101456326B1 (ko) | 3가, 이중특이적 항체 | |
| US20170306044A1 (en) | Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer | |
| CN102803295B (zh) | 双特异性、四价抗原结合蛋白 | |
| US20170327579A1 (en) | Bispecific antibodies against cd3epsilon and bcma | |
| JP2021511808A5 (enExample) | ||
| JP2022532534A5 (enExample) | ||
| JP2025511713A5 (enExample) | ||
| JP2025509272A5 (enExample) | ||
| IL272349B2 (en) | ANTI-CD137 antibodies | |
| EP1299419A2 (en) | Bispecific immunoglobulin-like antigen binding proteins and method of production | |
| JP2015520168A (ja) | 多重特異性抗体 | |
| WO2019234241A1 (en) | ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT | |
| WO2010112194A1 (en) | Antigen-binding polypeptides and multispecific antibodies comprising them | |
| KR20250008811A (ko) | 항-cd28 항체 및 이의 사용 방법 | |
| JP2024542978A5 (enExample) | ||
| JP7855148B2 (ja) | 前立腺特異的膜抗原（ｐｓｍａ）を標的とする組成物、並びにそれを作製及び使用するための方法 | |
| Gerspach | Activatable bispecific antibodies The current invention relates to bispecific antibodies wherein the binding affinity to one of the two antigens is reduced and which can be activated by tumor-or inflammation-tissue/disease specific proteases (eg tumor-or inflammation-specific proteases); and the preparation and use of such bispecific antibodies. | |
| JP2026505405A (ja) | 前立腺特異的膜抗原（ｐｓｍａ）を標的とする組成物、並びにそれを作製及び使用するための方法 | |
| NZ767462B2 (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| WO2025082777A1 (en) | Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules | |
| NZ767462A (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| KR20260011227A (ko) | 마스킹된 항체, 라이브러리 및 이의 사용 방법 | |
| NZ785553A (en) | Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses | |
| HK1184472B (zh) | 可活化的双特异性抗体 |